Wegovy is a GLP-1 receptor agonist (GLP-1 RA), which means it mimics the natural GLP-1 hormone
As the popularity of Ozempic and Wegovy persists in diabetes and obesity management, ongoing investigations into their side effects, such as gastroparesis, are essential for patient safety
Patients receiving an antipsychotic should be treated with structured lifestyle modifications to promote weight loss and weight gain prevention
The clinical approach is to manage symptoms supportively while allowing time for physiological adaptation
Risk Factors and Genetic Predispositions Individual responses to semaglutide vary significantly based on genetic variants in GLP-1 receptor pathways, metabolic genes, and gastrointestinal sensitivity loci
Dosing and administration Ozempic, Wegovy, and Mounjaro are all administered via once-weekly subcutaneous self-injection